Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 190

1.

Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.

Prondzynski M, Krämer E, Laufer SD, Shibamiya A, Pless O, Flenner F, Müller OJ, Münch J, Redwood C, Hansen A, Patten M, Eschenhagen T, Mearini G, Carrier L.

Mol Ther Nucleic Acids. 2017 Jun 16;7:475-486. doi: 10.1016/j.omtn.2017.05.008. Epub 2017 May 17.

2.

Blinded contractility analysis in hiPSC-cardiomyocytes in engineered heart tissue format: Comparison with human atrial trabeculae.

Mannhardt I, Eder A, Dumotier B, Prondzynski M, Krämer E, Traebert M, Söhren KD, Flenner F, Stathopoulou K, Lemoine MD, Carrier L, Christ T, Eschenhagen T, Hansen A.

Toxicol Sci. 2017 Apr 27. doi: 10.1093/toxsci/kfx081. [Epub ahead of print]

PMID:
28453742
3.

Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.

Flenner F, Geertz B, Reischmann-Düsener S, Weinberger F, Eschenhagen T, Carrier L, Friedrich FW.

J Physiol. 2017 Jun 15;595(12):3987-3999. doi: 10.1113/JP273769. Epub 2017 Feb 7.

PMID:
28090637
4.
5.

The embryological basis of subclinical hypertrophic cardiomyopathy.

Captur G, Ho CY, Schlossarek S, Kerwin J, Mirabel M, Wilson R, Rosmini S, Obianyo C, Reant P, Bassett P, Cook AC, Lindsay S, McKenna WJ, Mills K, Elliott PM, Mohun TJ, Carrier L, Moon JC.

Sci Rep. 2016 Jun 21;6:27714. doi: 10.1038/srep27714.

6.

Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.

Wijnker PJ, Friedrich FW, Dutsch A, Reischmann S, Eder A, Mannhardt I, Mearini G, Eschenhagen T, van der Velden J, Carrier L.

J Mol Cell Cardiol. 2016 Aug;97:82-92. doi: 10.1016/j.yjmcc.2016.03.003. Epub 2016 Apr 22.

PMID:
27108529
7.

Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.

Münch J, Avanesov M, Bannas P, Säring D, Krämer E, Mearini G, Carrier L, Suling A, Lund G, Patten M.

J Card Fail. 2016 Oct;22(10):845-50. doi: 10.1016/j.cardfail.2016.03.010. Epub 2016 Mar 24.

PMID:
27018569
8.

S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure.

Stathopoulou K, Wittig I, Heidler J, Piasecki A, Richter F, Diering S, van der Velden J, Buck F, Donzelli S, Schröder E, Wijnker PJ, Voigt N, Dobrev D, Sadayappan S, Eschenhagen T, Carrier L, Eaton P, Cuello F.

FASEB J. 2016 May;30(5):1849-64. doi: 10.1096/fj.201500048. Epub 2016 Feb 2.

9.

Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.

Najafi A, Sequeira V, Helmes M, Bollen IA, Goebel M, Regan JA, Carrier L, Kuster DW, Van Der Velden J.

Cardiovasc Res. 2016 May 15;110(2):200-14. doi: 10.1093/cvr/cvw026. Epub 2016 Jan 29.

PMID:
26825555
10.

Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities.

Judge DP, Neamatalla H, Norris RA, Levine RA, Butcher JT, Vignier N, Kang KH, Nguyen Q, Bruneval P, Perier MC, Messas E, Jeunemaitre X, de Vlaming A, Markwald R, Carrier L, Hagège AA.

J Cardiovasc Dev Dis. 2015;2(2):48-65. Epub 2015 Apr 21.

11.

Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis.

Aherrahrou Z, Schlossarek S, Stoelting S, Klinger M, Geertz B, Weinberger F, Kessler T, Aherrahrou R, Moreth K, Bekeredjian R, Hrabě de Angelis M, Just S, Rottbauer W, Eschenhagen T, Schunkert H, Carrier L, Erdmann J.

Basic Res Cardiol. 2016 Jan;111(1):6. doi: 10.1007/s00395-015-0522-5. Epub 2015 Dec 10.

PMID:
26659360
12.

Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.

Flenner F, Friedrich FW, Ungeheuer N, Christ T, Geertz B, Reischmann S, Wagner S, Stathopoulou K, Söhren KD, Weinberger F, Schwedhelm E, Cuello F, Maier LS, Eschenhagen T, Carrier L.

Cardiovasc Res. 2016 Jan 1;109(1):90-102. doi: 10.1093/cvr/cvv247. Epub 2015 Nov 3.

PMID:
26531128
13.

PLEKHM2 mutation leads to abnormal localization of lysosomes, impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction.

Muhammad E, Levitas A, Singh SR, Braiman A, Ofir R, Etzion S, Sheffield VC, Etzion Y, Carrier L, Parvari R.

Hum Mol Genet. 2015 Dec 20;24(25):7227-40. doi: 10.1093/hmg/ddv423. Epub 2015 Oct 12.

14.

Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.

Carrier L, Mearini G, Stathopoulou K, Cuello F.

Gene. 2015 Dec 1;573(2):188-97. doi: 10.1016/j.gene.2015.09.008. Epub 2015 Sep 8. Review.

PMID:
26358504
15.

The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.

Thottakara T, Friedrich FW, Reischmann S, Braumann S, Schlossarek S, Krämer E, Juhr D, Schlüter H, van der Velden J, Münch J, Patten M, Eschenhagen T, Moog-Lutz C, Carrier L.

J Mol Cell Cardiol. 2015 Oct;87:214-24. doi: 10.1016/j.yjmcc.2015.08.020. Epub 2015 Sep 3.

PMID:
26343497
16.

Media and technology use predicts ill-being among children, preteens and teenagers independent of the negative health impacts of exercise and eating habits.

Rosen LD, Lim AF, Felt J, Carrier LM, Cheever NA, Lara-Ruiz JM, Mendoza JS, Rokkum J.

Comput Human Behav. 2014 Jun;35:364-375.

17.

Targets for therapy in sarcomeric cardiomyopathies.

Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, Maier LS, Ashrafian H, Huke S, van der Velden J.

Cardiovasc Res. 2015 Apr 1;105(4):457-70. doi: 10.1093/cvr/cvv023. Epub 2015 Jan 29. Review.

18.

Research priorities in sarcomeric cardiomyopathies.

van der Velden J, Ho CY, Tardiff JC, Olivotto I, Knollmann BC, Carrier L.

Cardiovasc Res. 2015 Apr 1;105(4):449-56. doi: 10.1093/cvr/cvv019. Epub 2015 Jan 28. Review.

19.

Animal and in silico models for the study of sarcomeric cardiomyopathies.

Duncker DJ, Bakkers J, Brundel BJ, Robbins J, Tardiff JC, Carrier L.

Cardiovasc Res. 2015 Apr 1;105(4):439-48. doi: 10.1093/cvr/cvv006. Epub 2015 Jan 18. Review.

20.

Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.

Schlossarek S, Singh SR, Geertz B, Schulz H, Reischmann S, Hübner N, Carrier L.

Front Physiol. 2014 Dec 16;5:484. doi: 10.3389/fphys.2014.00484. eCollection 2014.

Supplemental Content

Loading ...
Support Center